Boosted by a significant commitment from insiders, Tesaro Inc. (NASDAQ:TSRO) became the first U.S. biotech to price an IPO at the midpoint of its proposed price range since Verastem Inc. (NASDAQ:VSTM) did so in January.

Tesaro was founded in 2010 by former executives of MGI Pharma Inc. (see BioCentury, March 7, 2011).